A new collaboration will see precision oncology company Erasca (Nasdaq: ERAS) working with the MD Anderson Cancer Center to evaluate multiple agents from the firm’s pipeline.
The Texan company has a particular focus on discovering, developing, and commercializing therapies for people with RAS/MAPK pathway-driven cancers.
Through its collaboration with the University of Texas-based research group, Erasca will seek to test candidates both as monotherapies and in combination treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze